The Grant Trap: Why Europe's Startup Funding Debate Needs Better Questions

This debate deserves more than applause or outrage. For those ready to move from position-taking to problem-solving, Human x AI Europe on May 19 in Vienna is where these conversations happen in person, with the people who can actually change the system.

A provocative argument landed in European tech discourse yesterday. Ale Maiano, writing in Sifted, made the case that European startups should stop beginning with public grants. The piece has already generated the predictable responses: enthusiastic agreement from those who see European innovation as over-bureaucratised, and defensive pushback from those who view public funding as essential infrastructure.

Both reactions miss what makes this argument worth examining carefully.

What the Argument Actually Claims

The core thesis deserves steel-manning before engagement. Maiano argues that when founders rely on grants too early, they optimise for eligibility criteria rather than market validation. The question shifts from "does anyone want this?" to "does this satisfy the funding programme's requirements?" Over time, this produces scientists who behave like applicants rather than entrepreneurs, prioritising grant proposals over products.

The evidence offered includes the case of Orbex, the Scottish aerospace company that entered administration in February 2026 after public funding increasingly filled gaps left by slowing private investment. The counter-example is Proxima Fusion, which raised private capital first to validate its technology before securing public support.

The argument is not that public funding should disappear. Maiano explicitly acknowledges that bodies like Innovate UK, UKRI, and Horizon have supported pioneering companies. The claim is narrower: the sequence matters, and private validation should precede public funding.

Where the Argument Lands

On the validation question, the critique has genuine force. There is a real phenomenon where grant-optimised companies develop technologies that satisfy programme criteria without ever testing whether customers will pay. The incentive structures of research grants and venture-backed companies genuinely differ, and founders who spend years navigating funding cycles may indeed arrive at market "untested as leaders," as Maiano puts it.

The Orbex example illustrates a real failure mode: public money flowing to companies that private capital has already begun to abandon. When governments become the funder of last resort for struggling ventures, taxpayers do absorb risk that the market has declined to take.

The overhead problem is also real. When university administrative structures capture significant portions of research grants, the capital intended for innovation gets diverted. This is a legitimate structural critique that deserves attention from policymakers.

Where the Argument Overshoots

The argument becomes less convincing when it treats "grants" as a single category. Consider what gets bundled together under this term:

Research grants fund basic science before any commercial application exists. These are not meant to validate startups; they are meant to expand the frontier of knowledge. Criticising them for not producing market-ready companies misunderstands their purpose.

Proof-of-concept funding helps researchers determine whether laboratory results can translate to real-world applications. This is pre-company work that private capital rarely touches because the risk profile is too uncertain.

Startup grants provide non-dilutive capital to early-stage companies. These compete directly with angel and seed investment and raise the validation questions Maiano identifies.

Scale-up support helps proven companies expand. This is where Proxima Fusion's public funding came in, and where Maiano agrees public money can play a valuable role.

Treating these as a single phenomenon obscures more than it reveals. The critique applies most forcefully to startup grants that substitute for private validation. It applies least to basic research funding that precedes any commercial intent.

The Sequencing Question

The strongest version of Maiano's argument is about sequencing, not about public funding per se. The claim is that private validation should come first because it forces harder questions about markets, customers, and execution.

This raises a genuine question: what counts as validation? A customer letter of intent? A paying pilot? A term sheet from a reputable investor? The answer matters because different types of companies face different validation challenges.

A software startup can often find customers quickly. A fusion energy company cannot. A pharmaceutical company faces regulatory timelines that no amount of customer enthusiasm can accelerate. The appropriate validation sequence depends on the sector, the technology readiness level, and the nature of the market being addressed.

European founders have noted that the continent's caution may sometimes reflect foresight rather than weakness. The WeWork implosion demonstrated what happens when private capital validates companies that lack sustainable unit economics. Private validation is not automatically superior validation; it is simply different validation.

What Policymakers Should Actually Consider

Rather than accepting or rejecting the "grants are bad" framing, policymakers might ask more precise questions:

At what stage does public funding enter? Funding basic research is different from funding companies. The critique applies most strongly when public money substitutes for private validation at the company formation stage.

What does the funding require? Grants that demand matched private investment create different incentives than grants that fund companies regardless of market interest. The match-funding critique in Maiano's piece deserves attention: if companies seek investors primarily to unlock public money, the validation logic inverts.

What happens to the overhead? If administrative structures capture large portions of research funding, that is a design problem worth fixing regardless of one's view on grants generally.

What is the counterfactual? In sectors where private capital is scarce, the alternative to public funding may not be private funding. It may be no funding at all, and no companies emerging from European research.

The Deeper Question

Europe's innovation debate often oscillates between two poles: the view that the continent is hopelessly bureaucratic and the view that it simply needs more public investment. Neither captures the actual complexity.

The real question is not whether public funding is good or bad. The question is: what institutional designs produce companies that can compete globally while serving public interests? This requires thinking about incentive structures, validation mechanisms, and the relationship between research and commercialisation with more precision than the current debate typically offers.

Maiano's piece contributes something valuable: it names a real failure mode and forces a conversation about sequencing. The response should not be defensive dismissal. It should be disaggregation: which parts of this critique apply to which types of funding, at which stages, in which sectors?

That is the conversation worth having. And it is a conversation that requires policymakers, investors, and founders to sit in the same room and argue about specifics rather than trading position statements across op-ed pages.

The strongest European companies will likely emerge from ecosystems that get this balance right: public funding that supports research and de-risks genuinely uncertain technologies, combined with private capital that forces market discipline at the company-building stage. The question is not grants versus no grants. The question is: what kind of system produces both scientific ambition and commercial rigour?

That question remains open. And answering it well matters more than winning the argument.